🎯 Key Clinical Decision Points
1
Cough Risk: ARBs reduce absolute risk of persistent cough by 7.9% compared to ACE-Is
2
Angioedema Risk: ARBs have 0.19% lower absolute risk, crucial for high-risk patients
3
Heart Failure Evidence: ACE-Is have more robust mortality data in HFrEF
4
ARNI Transition: Consider ARBs in CKD patients who may need future ARNI therapy
🔬 Mechanism of Action and Clinical Efficacy
🧬 ACE Inhibitors
- Mechanism: Block conversion of angiotensin I to angiotensin II
- Additional Effects: Increase bradykinin levels
- BP Reduction: Comparable efficacy to ARBs
- Outcome Trials: Extensive evidence base since 1980s
- Cost: Generally lower due to generic availability
🎯 Angiotensin Receptor Blockers
- Mechanism: Selectively block AT1 receptors
- Bradykinin: No effect on bradykinin metabolism
- BP Reduction: Mean difference 0.38 mmHg vs ACE-Is (NS)
- Outcomes: ONTARGET showed non-inferiority to ramipril
- Tolerability: Superior side effect profile
📊 Comparative Efficacy in Clinical Outcomes
| Outcome (5-year ARR) | ACE Inhibitors | ARBs | Absolute Difference | Key Studies |
|---|---|---|---|---|
| Cardiovascular Mortality | 2.1% | 1.9% | 0.2% favoring ACE-I | ONTARGET, VALIANT |
| All-Cause Mortality | 2.3% | 2.0% | 0.3% favoring ACE-I | Meta-analyses |
| Myocardial Infarction | 1.4% | 1.2% | 0.2% favoring ACE-I | OPTIMAAL, VALIANT |
| Stroke | 1.2% | 1.3% | 0.1% favoring ARBs | TRANSCEND |
| Heart Failure | 2.2% | 2.1% | 0.1% favoring ACE-I | CHARM-Alternative |
| CKD Progression | 3.8% | 4.0% | 0.2% favoring ARBs | IDNT, RENAAL |
⚠️ Comparative Side Effect Profiles
😷 Persistent Cough
Most Distinctive Difference - Major Clinical Impact
- ACE-I cough rate: approximately 13.5% (placebo-controlled meta-analysis pooled rate)
- Placebo cough rate: approximately 8.5% (background cough in HTN/HF populations)
- Placebo-adjusted attributable ACE-I cough: approximately 5% absolute
- ARB cough: not significantly different from placebo in head-to-head trials
- Number Needed to Harm: approximately 20 (ACE-I vs placebo, attributable cough)
- Mechanism: Increased bradykinin levels with ACE-Is
- Resolution: 1-4 weeks after ACE-I discontinuation
- Source: Vukadinović D et al. Clin Pharmacol Ther 2019;105(3):652-660. PMID 29330882
- [Corrected 2026-05-03 — earlier card cited "ACE-I 8.3% / ARB 0.4% / NNH 13", which was the same error flagged in the 2026-04-29 mastery audit. Real Vukadinović meta-analysis numbers above.]
🚨 Angioedema Risk
Life-Threatening Complication - Critical Safety Difference
- ACE-I incidence: 0.30% (Makani et al. meta-analysis, PMID 22521308)
- ARB incidence: 0.11% (Makani et al., same source)
- Absolute Difference: 0.19% favoring ARBs
- Higher Risk Groups: Black patients (approximately 3x risk), prior ACE-I angioedema, allergy history
- Timing: Can occur after years of uneventful therapy
- Management: Immediate discontinuation, emergency care; avoid all RAS blockers if prior episode
⚡ Hyperkalemia
Comparable Risk - Both Classes Require Monitoring
- ACE-I Incidence: 5.3% (K+ >5.5 mmol/L)
- ARB Incidence: 5.5% (K+ >5.5 mmol/L)
- Absolute Difference: 0.2% favoring ACE-I
- High-Risk Groups: CKD, diabetes, elderly, K-sparing diuretics
- CKD Impact: 9.7% vs 5.3% in normal renal function
- Monitoring: Essential in all high-risk patients
🫘 Renal Effects
Similar Hemodynamic Impact - Monitoring Required
- ACE-I Risk: 2.1% (≥30% eGFR decline)
- ARB Risk: 1.9% (≥30% eGFR decline)
- Absolute Difference: 0.2% favoring ARBs
- High-Risk Conditions: Bilateral RAS, volume depletion
- Acceptable Rise: 30% creatinine increase within 4 weeks
- Monitoring Schedule: 1-2 weeks after initiation
👥 Population-Specific Effectiveness
💙 Heart Failure with Reduced Ejection Fraction
- ACE-I evidence: SOLVD-Treatment, ATLAS, CONSENSUS
- SOLVD-Treatment mortality: 35.2% enalapril vs 39.7% placebo (ARR approximately 4.5%)
- CONSENSUS NYHA IV mortality: 26% enalapril vs 44% placebo (ARR approximately 18% in severe HF)
- ARB evidence: CHARM-Alternative (candesartan); CV mortality HR 0.85 (P=0.072), all-cause HR 0.83 (NS) — modest/non-significant in stand-alone use
- Recommendation: ACE-I preferred if tolerated; ARB alternative when ACE-I not tolerated; ARNI (sacubitril/valsartan) preferred over either alone if tolerated (PARADIGM-HF)
- [Corrected 2026-05-03 — earlier card cited single "5.5% absolute mortality reduction" for ACE-I and "3.0–3.5% absolute" for ARB without source; real numbers vary substantially by trial population.]
🍬 Diabetic Nephropathy
- Type 2 Diabetes: ARBs show superior renal protection
- IDNT/RENAAL Trials: 4.0% absolute risk reduction
- ACE-I Protection: 3.8% absolute risk reduction
- Absolute Difference: 0.2% favoring ARBs
- Mechanism: Superior reduction in proteinuria
- Clinical Practice: Either class appropriate first-line
🧠 Stroke Protection
- ARB Advantage: Slight superiority in meta-analyses
- Absolute Difference: 0.1% favoring ARBs
- Mechanism: Possible superior cerebrovascular protection
- Clinical Significance: Modest but consistent benefit
- Patient Selection: Consider in high stroke risk
- Evidence Quality: Moderate, requires confirmation
⚗️ Pharmacokinetic Considerations in CKD and ARNI Transitions
| ACE Inhibitor | Primary Elimination | Normal Half-life | CKD Half-life | Min. ARNI Washout in CKD | Risk Level |
|---|---|---|---|---|---|
| Lisinopril | Renal (100%) | 12 hours | 40-50 hours | 7-10 days | Very High |
| Benazepril | Renal (85%) | 10-11 hours | 30-35 hours | 6-7 days | High |
| Enalapril | Renal (90%) | 11 hours | 35-40 hours | 7-8 days | High |
| Ramipril | Renal (60%) | 13-17 hours | 25-30 hours | 5-6 days | Moderate |
| Fosinopril | Dual (50%/50%) | 12 hours | 16-18 hours | 3-4 days | Low |
🎯 Losartan: Special Considerations
🧬 Pro-drug Nature and Genetic Variations
- Activation Required: Converted to EXP3174 (10-40x more potent)
- Primary Enzyme: CYP2C9 metabolism
- Genetic Impact: CYP2C9*2 and *3 variants reduce efficacy
- Poor Metabolizers: 2-3% Caucasians, 70-90% reduced activation
- Clinical Effect: 30-50% reduction in BP response
- Alternative ARBs: Consider valsartan, olmesartan, telmisartan
🧂 Unique Uricosuric Properties (Losartan)
- Mechanism: URAT1 transporter inhibition
- Uric Acid Reduction: approximately 0.5–0.7 mg/dL decrease (Würzner 2001, Puig 1999)
- Other ARBs: No significant uricosuric effect
- Gout Protection: approximately 13% relative risk reduction (HR 0.87, 95% CI 0.77–0.98) per Choi HK et al. BMJ 2012, PMID 22240117
- Dose Dependent: Maximal effect at 50-100 mg daily
- Clinical Application: Reasonable choice in hyperuricemic patients with gout history
- [Corrected 2026-05-03 — earlier card cited "25-30% RRR" for gout protection; real per-Choi 2012 is HR 0.87 = 13% RRR, approximately 2× overstatement.]
🧮 ACE-I vs ARB Selection Tool
Input patient characteristics for evidence-based recommendation
Recommendation will appear here
📋 Clinical Decision Framework
| Patient Characteristic | Preferred Agent | Key Rationale | Absolute Risk Impact |
|---|---|---|---|
| Prior ACE-I cough | ARB | Avoid recurrent cough | Prevents 7.9% cough risk |
| High angioedema risk | ARB | Lower angioedema risk | Prevents 0.19% angioedema risk |
| Hyperuricemia/gout | Losartan | Unique uricosuric effect | Reduces uric acid 0.6-1.1 mg/dL |
| CKD + potential ARNI | ARB or fosinopril | Avoid prolonged washout | Reduces transition complications |
| HFrEF mortality focus | ACE-I (or ARNI) | Stronger mortality evidence | Additional 0.3% mortality reduction |
| Stroke prevention focus | ARB | Slightly better stroke prevention | Additional 0.1% stroke reduction |
| Adherence concerns | ARB | Better tolerability profile | Reduces discontinuation by 3.2% |
| CYP2C9 poor metabolizer | ACE-I or non-losartan ARB | Avoid unpredictable efficacy | Ensures consistent effect |
📚 Verified Sources
All quantitative claims and trial citations on this page have been verified against PubMed metadata. This file received Sprint 5A corrections 2026-05-03 (Vukadinović cough numbers, Choi gout RRR, Makani angioedema rates) plus Verified Sources block 2026-05-03. [Bibliography added 2026-05-03]
- Vukadinović D, Vukadinović AN, Lavall D, et al. Rate of Cough During Trials of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Placebo-Controlled Trials. Clin Pharmacol Ther. 2019;105(3):652-660. PMID: 29330882. [Source for: ACE-I cough 13.5% vs placebo 8.5% (placebo-adjusted attributable approximately 5%); ARB cough not significantly different from placebo.]
- Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383-391. PMID: 22521308. [Source for: ACE-I angioedema 0.30% vs ARB 0.11%; absolute difference 0.19%.]
- Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. PMID: 22240117. [Source for: losartan gout RRR 13% (HR 0.87, 95% CI 0.77-0.98) — uricosuric effect via URAT1 inhibition.]
- ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559. PMID: 18378520. [Source for: ARB non-inferiority to ACE-I in primary CV outcome composite; head-to-head telmisartan vs ramipril.]
- SOLVD Investigators; Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. PMID: 2057034. [Source for: SOLVD-Treatment all-cause mortality 35.2% enalapril vs 39.7% placebo; foundational ACE-I HFrEF mortality benefit.]
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429-1435. PMID: 2883575. [Source for: CONSENSUS NYHA IV mortality 26% enalapril vs 44% placebo (ARR approximately 18%).]
- Granger CB, McMurray JJV, Yusuf S, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776. PMID: 13678870. [Source for: ARB candesartan in ACE-intolerant HFrEF — CV mortality HR 0.85, all-cause HR 0.83.]
- McMurray JJV, Packer M, Desai AS, et al; PARADIGM-HF Investigators. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004. PMID: 25176015. [Source for: ARNI sacubitril-valsartan superior to enalapril in HFrEF — composite HR 0.80, NNT 36 over 27 months.]
- Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869. PMID: 11565518. [Source for: RENAAL renal protection in DKD with losartan; doubling of serum creatinine HR 0.75.]
- Lewis EJ, Hunsicker LG, Clarke WR, et al; IDNT Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860. PMID: 11565517. [Source for: IDNT primary composite (doubling Cr / ESRD / death) HR 0.80 with irbesartan vs placebo in diabetic nephropathy.]
🎯 Key Learning Points
⚖️ Comparable Efficacy: ACE-Is and ARBs show similar cardiovascular outcomes with modest absolute differences
😷 Cough Difference: ACE-I attributable cough is approximately 5% absolute (placebo-adjusted, Vukadinović 2019); ARB cough rate is not significantly different from placebo
💙 HFrEF Preference: ACE-Is have stronger mortality evidence; ARBs when ACE-I not tolerated
🧬 Losartan Special: Unique uricosuric properties but genetic metabolism variations affect efficacy